GLP-1
Galapagos NV announces a share capital increase as a result of a public offering of American Depositary Shares.
Galapagos NV and MorphoSys AG announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.
Galapagos NV announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares (“ADSs”) at $116.50 per ADS, before underwriting discounts.
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
BioChaperone® Pramlintide Insulin (BC Pram Ins) is the first product to clinically demonstrate the feasibility of a fixed-ratio co-formulation of pramlintide and human insulin
Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
PRESS RELEASES